glp 1 drugs adverse effects of GLP-1 class drugs. Gastrointestinal issues are Nutritional Side Effects of GLP-1

If we recall that approximately 25% of total weight loss in persons with obesity is accounted for by FFM, the authors found that fat free mass accounted for 33%, 39%, and 25% of total weight loss for retatrutide ( Phase 2 data only, not yet FDA approved), semaglutide and tirzepatide respectively whereas fat mass loss accounted for 67%, 61%, and 75% respectively

After treatment with BN for 3 months, BMI, fasting blood glucose, glycosylated hemoglobin, visceral and subcutaneous fat, silk protein E1, leptin, C-reactive protein (CRP), and tumor necrosis factor decreased significantly

They're just a minor bump in the road

Why the backward system